RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients.

TPS3111 Background: Despite extensive research in NSCLC treatment, overall survival remains insufficient. Immunotherapy has become a viable treatment to help the immune system to control or elimina...